Highly conformal radiotherapy for T1-2 n0 (=3 cm, <50% of the anal circumference) anal cancers: outcome and toxicity

被引：0
|
作者：
Lestrade, L. [1 ]
De Bari, B. [2 ]
Kountouri, M. [1 ]
Jumeau, R. [2 ]
Ozsahin, M. [2 ]
Zilli, T. [1 ]
机构：
[1] Geneva Univ Hosp, Dept Radiat Oncol, Geneva, Switzerland
[2] Vaud Univ Hosp Ctr, Dept Radiat Oncol, Lausanne, Switzerland
来源：
RADIOTHERAPY AND ONCOLOGY | 2015年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP-1220
引用
收藏
页码：S660 / S661
页数：2
相关论文
共 20 条
  • [11] Do patients with low-risk (T1-2 [<3 cm] N0, HR+) breast cancer and anti-hormone treatment need adjuvant radiation therapy? A meta-analysis of randomized trials.
    Matuschek, Christiane
    Boelke, Edwin
    Kammers, Kai
    Budach, Wilfried
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [12] Female breast cancers (T1-2, N0, M0, HR+, HER2-) with an intermediate genetic-based recurrence risk: a real-world estimate in Italy
    Crocetti, Emanuele
    Ravaioli, Alessandra
    Amadori, Dino
    Mancini, Silvia
    Vattiato, Rosa
    Giuliani, Orietta
    Baldacchini, Flavia
    Falcini, Fabio
    [J]. TUMORI JOURNAL, 2019, 105 (06): : 483 - 487
  • [13] Early-stage Node-negative (T1-T2N0) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy
    Franco, Pierfrancesco
    Arcadipane, Francesca
    Ragona, Riccardo
    Mistrangelo, Massimiliano
    Cassoni, Paola
    Rondi, Nadia
    Morino, Mario
    Racca, Patrizia
    Ricardi, Umberto
    [J]. ANTICANCER RESEARCH, 2016, 36 (04) : 1943 - 1948
  • [14] Cost-minimisation and cost-effectiveness analysis comparing transoral CO2 laser cordectomy, laryngofissure cordectomy and radiotherapy for the treatment of T1-2, N0, M0 glottic carcinoma
    Diaz-de-Cerio, Pedro
    Preciado, Julian
    Santaolalla, Francisco
    Sanchez-del-Rey, Ana
    [J]. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2013, 270 (04) : 1181 - 1188
  • [15] Omission of neoadjuvant radiotherapy for clinical T2/N1 and T3N0/1 middle and low rectal cancers with safe circumferential resection margins
    Lee, Kyung-Ha
    Kim, Jin-Soo
    Kim, Ji-Yeon
    [J]. ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2022, 102 (05) : 281 - 288
  • [16] A Phase II Study of Accelerated Hypofractionated 3-Dimensional Conformal Radiotherapy for Inoperable T1-3 N0 M0 Non-Small Cell Lung Cancer: NCIC CTG BR.25
    Cheung, P.
    Faria, S.
    Ahmed, S.
    Chabot, P.
    Greenland, J.
    Kurien, E.
    Mohamed, I.
    Wright, J.
    Ding, K.
    O'Callaghan, C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S210 - S211
  • [17] De-Escalation of Radiation Therapy in Patients with cT1-T2 (< 3 cm) N0 HER2+Breast Cancer Treated With Neoadjuvant Systemic Therapy With Pathologic Complete Response at the Time of Breast Conserving Surgery
    Raj, R.
    Jhawar, S. R.
    Stover, D.
    Park, K. U.
    Beyer, S.
    Healy, E.
    White, J. R.
    Bazan, J. G., Jr.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E209 - E210
  • [18] Phase II Study of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy for Stage T1-3 N0 M0 Non-Small Cell Lung Cancer: NCIC CTG BR.25
    Cheung, Patrick
    Faria, Sergio
    Ahmed, Shahida
    Chabot, Pierre
    Greenland, Jonathan
    Kurien, Elizabeth
    Mohamed, Islam
    Wright, James R.
    Hollenhorst, Helmut
    de Metz, Catherine
    Campbell, Holly
    Thi Toni Vu
    Karvat, Anand
    Wai, Elaine S.
    Ung, Yee C.
    Goss, Glenwood
    Shepherd, Frances A.
    O'Brien, Patti
    Ding, Keyue
    O'Callaghan, Chris
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (08)
  • [19] Phase II Study of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy for Stage T1-3 N0 M0 Non-Small Cell Lung Cancer: NCIC CTG BR.25 (vol 106, dju164, 2014)
    Cheung, Patrick
    Faria, Sergio
    Ahmed, Shahida
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (01)
  • [20] Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival
    Eremin, Jennifer
    Cowley, Ged
    Walker, Leslie G.
    Murray, Elisabeth
    Stovickova, Monika
    Eremin, Oleg
    [J]. SPRINGERPLUS, 2015, 4
12